Mustang ties the knot with Fred Hutch on next-gen CAR-T for lymphoma
Back in early February, Mustang Bio — a sub of Fortress Biotech $FBIO — said it had raised a whopping $94.5 million to bolster its work on new CAR-T therapies. And this morning it’s followed through with a licensing pact forged with the prestigious Fred Hutch, where it will now push a new Phase I/II clinical study in B-cell non-Hodgkin lymphomas.
This new program comes out of the labs of Oliver Press and Brian Till at the Hutch. They’ve been working on a CAR-T that can express a CD20-specific chimeric antigen receptor.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
